Article Text

PDF
OP0076 Risk of developing additional immune mediated manifestations for patients with systemic arthritides
  1. D Aletaha1,
  2. R Panaccione2,
  3. M Davis3,
  4. S Johnson3,
  5. M Skup4,
  6. V Garg4
  1. 1Medical University of Vienna, Vienna, Austria
  2. 2Univerity of Calgary, Calgary, Canada
  3. 3Medicus Economics, LLC, Milton
  4. 4AbbVie Inc., North Chicago, United States

Abstract

Background Patients with the systemic arthritides ankylosing spondylitis [AS], psoriatic arthritis [PsA], rheumatoid arthritis [RA] may develop additional, non-musculoskeletal immune mediated manifestations (nms-IMMs).

Objectives To compare the risk of developing nms-IMMs between patients with and without an existing AS, PsA, or RA.

Methods Risk for nms-IMMs was estimated in the MarketScan Commercial Claims and Encounters database (1/2006–9/2015) for case patients with AS, PsA, RA (the “systemic arthritides”). Up to 1,000 controls were matched with replacement by age, sex, state of residence and insurance type to case patients aged 18–64. The systemic arthritides (“cases”) were identified by ICD-9 diagnosis codes on ≥2 medical claims ≥30 days apart. A case patient's earliest nms-IMM claim was designated as the index date for the case and all matched controls. Onset of 6 nms-IMDs was identified by the first post-index claim: celiac disease [CE], hidradenitis suppurativa [HS], inflammatory bowel disease [IBD], lupus [SLE], psoriasis [PsO], uveitis [UV]; some of these are well-known manifestations of seronegative spondylarthropathies, like PsA and AS; some are not. All subjects had continuous health plan enrollment for ≥365 days before and after index date. Cumulative incidence of nms-IMMs was assessed at 5 years. Their risk was analyzed with stratified Cox proportional hazards models. Standard errors were adjusted for clustering by case-control match group.

Results Among 117,794 cases, mean age was 49 years and 71% were female. Mean number of matched controls per case was 664. Across the 3 initial cohorts of patients with AS, PsA, or RA, median follow-up ranged 939–972 days for cases and 931–950 days for controls. Among case patients, 5-year cumulative incidence of any nms-IMM occurrence was 17.5% for AS, 41.8% for PsA, and 14.4% for RA. Patients with nms-IMMs had significantly higher risk than matched controls of developing each, any 1, or any 2 of the 6 manifestations (P≤0.002) (Table).

Conclusions The risk of developing non-musculoskeletal manifestations was significantly higher for patients with AS, PsA, and RA than for matched controls. These included not only the well-known manifestations of PsA and AS but also others like manifestations leading to claims for SLE, celiac disease or HS. When managing these systemic arthritides, surveillance for additional immune mediated manifestation is warranted.

Acknowledgements Design, study conduct, and financial support for the study were provided by AbbVie Inc. AbbVie participated in the interpretation of data, review, and approval of the abstract; all authors contributed to the development of the abstract and maintained control over the final content. Medical writing services were provided by Andrew Epstein of Medicus Economics and were funded by AbbVie.

Disclosure of Interest D. Aletaha Grant/research support from: AbbVie, AstraZeneca, BMS, Eli Lilly, Grünenthal, Jansen, Medac, Merck, Mitsubishi Tanabe, Novo Nordisk, Pfizer, and Sanofi/Regeneron, Consultant for: AbbVie, AstraZeneca, BMS, Eli Lilly, Grünenthal, Jansen, Medac, Merck, Mitsubishi Tanabe, Novo Nordisk, Pfizer, and Sanofi/Regeneron, Speakers bureau: AbbVie, AstraZeneca, BMS, Eli Lilly, Grünenthal, Jansen, Medac, Merck, Mitsubishi Tanabe, Novo Nordisk, Pfizer, and Sanofi/Regeneron, R. Panaccione Consultant for: AbbVie, Amgen, AstraZeneca, Axcan Pharma (now Aptalis), Biogen Idec, Bristol-Myers Squibb, Centocor, ChemoCentryx, Eisai Medical Research Inc, Elan Pharmaceuticals, Ferring, Genentech, GlaxoSmithKline, Janssen, Merck Sharp & Dohme Corp, Millennium Pharmaceuticals Inc (now Takeda), Ocera Therapeutics Inc, Otsuka America Pharmaceutical, Pfizer, Shire Pharmaceuticals, Prometheus Laboratories, Schering-Plough Corporation, Synta Pharmaceuticals Corp, Teva, UCB Pharma, and Warner Chilcott, Speakers bureau: AbbVie, Amgen, AstraZeneca, Axcan Pharma (now Aptalis), Biogen Idec, Bristol-Myers Squibb, Centocor, ChemoCentryx, Eisai Medical Research Inc, Elan Pharmaceuticals, Ferring, Genentech, GlaxoSmithKline, Janssen, Merck Sharp & Dohme Corp, Millennium Pharmaceuticals Inc (now Takeda), Ocera Therapeutics Inc, Otsuka America Pharmaceutical, Pfizer, Shire Pharmaceuticals, Prometheus Laboratories, Schering-Plough Corporation, Synta Pharmaceuticals Corp, Teva, UCB Pharma, and Warner Chilcott, M. Davis Employee of: Medicus, which has received payment from AbbVie to assist with data analysis, S. Johnson Employee of: Medicus, which has received payment from AbbVie to assist with data analysis, M. Skup Shareholder of: AbbVie, Employee of: AbbVie, V. Garg Shareholder of: AbbVie, Employee of: AbbVie

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.